[
    [
        {
            "time": "2023-03-15",
            "original_text": "Eli Lilly (LLY) Gains But Lags Market: What You Should Know",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Gains",
                    "Lags Market"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly (LLY) Gains But Lags Market: What You Should Know",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-03-15",
            "original_text": "The Zacks Analyst Blog Highlights: Mastercard, Eli Lilly, Citigroup, Advanced Micro Devices and Square",
            "features": {
                "keywords": [
                    "Zacks Analyst Blog",
                    "Mastercard",
                    "Eli Lilly",
                    "Citigroup",
                    "Advanced Micro Devices",
                    "Square"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "financial services",
                    "technology"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Zacks Analyst Blog Highlights: Mastercard, Eli Lilly, Citigroup, Advanced Micro Devices and Square",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-03-15",
            "original_text": "Bluebird Bio, Biomarin Tabbed as Top Acquisition Targets",
            "features": {
                "keywords": [
                    "Bluebird Bio",
                    "Biomarin",
                    "Acquisition Targets"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Bluebird Bio, Biomarin Tabbed as Top Acquisition Targets",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-03-15",
            "original_text": "PREVAIL THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prevail Therapeutics Inc. - PRVL",
            "features": {
                "keywords": [
                    "Prevail Therapeutics",
                    "Investor Alert",
                    "Kahn Swick & Foti",
                    "Proposed Sale"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "PREVAIL THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prevail Therapeutics Inc. - PRVL",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]